Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases (scientific article published on 14 January 2009)

Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy.

Q33494165

Pneumocystis carinii pneumonia in patients without HIV infection

Q34153890

(1-->3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia.

Q35226026

Clinical characteristics of Pneumocystis carinii pneumonia in patients with connective tissue diseases

Q38482611

Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality

Q39499935

Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases.

Q40705059

Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS.

Q44990606

Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease

Q45240864

Risk factors for hospital-acquired bacteremia

Q46853419

Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases.

Q54731023

Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients

Q70936213

Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases

Q71598401

P433

issue

P304

page(s)

1327-1330

P577

publication date

2009-01-14

P1433

published in

Rheumatology International

Q15763689

P1476

title

Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases

P478

volume

Reverse relations

cites work (P2860)

Q40046796	A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection
Q36329163	A Systematic Review and Meta-Analysis of the Data Behind Current Recommendations for Corticosteroids in Non-HIV-Related PCP: Knowing When You Are on Shaky Foundations
Q90549466	Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies
Q55080458	Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients.
Q33856426	Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes
Q35793693	Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death
Q38221817	Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases
Q94547575	Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia
Q64117776	Prognostic significance of crazy paving ground grass opacities in non-HIV Pneumocystis jirovecii pneumonia: an observational cohort study

P6179	Dimensions Publication ID	1018547479
P356	DOI	10.1007/S00296-009-0857-Z
P698	PubMed publication ID	19142640